Skip to main content

Table 2 Association between clinical parameters and evolution in 120 patients with ITP

From: Impact of reticulin stain in clinical outcome of Immune Thrombocytopenic Purpura (ITP): a pathologist perspective

 

Favorable outcome (n = 89)

Unfavorable outcome

(n = 31)

p-value*

n

%

n

%

Petechiae

60

67.4

20

64.5

0.466

Ecchymosis

71

79.8

23

74.2

0.339

Hematoma

19

21.3

6

19.4

0.518

Epistaxis

29

32.6

13

41.9

0.234

Purpura

21

23.6

6

19.4

0.415

Oral bleeding

45

50.6

16

51.6

0.543

Mucosal bleeding

41

46.1

13

41.9

0.427

Internal bleedinga

12

13.5

4

12.9

0.609

Anemia

18

20.2

6

19.4

0.572

Leukopenia

1

1.1

0

0.0

0.742

Lymphopenia

16

18.0

3

9.7

0.214

Thrombocytopenia

83

93.3

29

93.5

0.660

Infection

23

25.8

4

12.9

0.105

Splenomegaly

4

4.5

1

3.2

0.615

Non-hematological neoplasia

1

1.1

2

6.5

0.165

Chemotherapy/radiation therapy

0

0.0

1

3.2

0.258

Use of systemic medication

23

25.8

9

29.0

0.449

Systemic arterial hypertension

13

14.6

14

45.2

0.001

Diabetes mellitus

5

5.6

3

9.7

0.340

Dyslipidemia

5

5.6

6

19.4

0.033

Obesity

5

5.6

5

16.1

0.079

Smoking

13

11.2

3

9.7

0.555

Past autoimmune disease

4

4.5

1

3.2

0.615

Hypothyroidism

3

3.4

3

9.7

0.178

Viral hepatitis

3

3.4

6

19.4

0.009

H. pylori gastritis

6

6.7

2

6.4

0.622

  1. *Statistical tests used: Chi-square and Fisher exact. a Hemorrhages of the gastrointestinal tract, respiratory tract, or central nervous system